Literature DB >> 10064838

Ferritin, transferrin and iron concentrations in the cerebrospinal fluid of multiple sclerosis patients.

S M LeVine1, S G Lynch, C N Ou, M J Wulser, E Tam, N Boo.   

Abstract

The concentrations of ferritin, transferrin and iron were measured in the cerebrospinal fluid (CSF) of multiple sclerosis (MS) and control patients. Ferritin levels were significantly elevated in the CSF of chronic progressive active MS patients (4.71+/-0.54 ng/ml) compared to levels in normal individuals (3.07+/-0.17 ng/ml). MS patients with active or stable relapsing-remitting disease had ferritin levels that were comparable to those found in normal individuals. There were no significant differences in transferrin or iron levels in the CSF between MS and normal individuals. Both ferritin and transferrin levels were elevated in patients that had high CSF IgG values but not in patients with a high IgG index. Since ferritin binds iron, the increase of CSF ferritin levels in chronic progressive MS patients could be a defense mechanism to protect against iron induced oxidative injury. Ferritin levels could be a laboratory measure that helps to distinguish between chronic progressive and relapsing-remitting MS. Copyright 1999 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10064838     DOI: 10.1016/s0006-8993(98)01360-2

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  25 in total

1.  Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity.

Authors:  Robert A Bermel; Srinivas R Puli; Richard A Rudick; Bianca Weinstock-Guttman; Elizabeth Fisher; Frederick E Munschauer; Rohit Bakshi
Journal:  Arch Neurol       Date:  2005-09

Review 2.  Pathogenic implications of iron accumulation in multiple sclerosis.

Authors:  Rachel Williams; Cassandra L Buchheit; Nancy E J Berman; Steven M LeVine
Journal:  J Neurochem       Date:  2011-11-11       Impact factor: 5.372

3.  Identification of differentially expressed proteins in experimental autoimmune encephalomyelitis (EAE) by proteomic analysis of the spinal cord.

Authors:  Tong Liu; K Christian Donahue; Jun Hu; Michael P Kurnellas; Jennifer E Grant; Hong Li; Stella Elkabes
Journal:  J Proteome Res       Date:  2007-06-16       Impact factor: 4.466

4.  Cerebrospinal fluid ferritin in chronic hydrocephalus after aneurysmal subarachnoid hemorrhage.

Authors:  Hidenori Suzuki; Masatoshi Muramatsu; Katsuhiro Tanaka; Hiroaki Fujiwara; Tadashi Kojima; Waro Taki
Journal:  J Neurol       Date:  2006-04-28       Impact factor: 4.849

5.  Transverse relaxation of cerebrospinal fluid depends on glucose concentration.

Authors:  A Daoust; S Dodd; G Nair; N Bouraoud; S Jacobson; S Walbridge; D S Reich; A Koretsky
Journal:  Magn Reson Imaging       Date:  2017-08-03       Impact factor: 2.546

6.  Hyperferritinemia is associated with serologic antiphospholipid syndrome in SLE patients.

Authors:  Gisele Zandman-Goddard; Hedi Orbach; Nancy Agmon-Levin; Mona Boaz; Howard Amital; Zoltan Szekanecz; Gabriella Szucs; Josef Rovensky; Emese Kiss; Nadia Corocher; Andrea Doria; Ljudmila Stojanovich; Francesca Ingegnoli; Pier Luigi Meroni; Blaz Rozman; Jesus Gomez-Arbesu; Miri Blank; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2013-02       Impact factor: 8.667

7.  Albumin and Protein Oxidation are Predictors that Differentiate Relapsing-Remitting from Progressive Clinical Forms of Multiple Sclerosis.

Authors:  Sayonara R Oliveira; Ana Paula Kallaur; Edna M V Reiche; Damacio R Kaimen-Maciel; Carolina Panis; Marcell Alysson B Lozovoy; Helena K Morimoto; Michael Maes; Isaias Dichi; Andrea Name Colado Simão
Journal:  Mol Neurobiol       Date:  2016-03-30       Impact factor: 5.590

8.  Iron and volume in the deep gray matter: association with cognitive impairment in multiple sclerosis.

Authors:  C M Modica; R Zivadinov; M G Dwyer; N Bergsland; A R Weeks; R H B Benedict
Journal:  AJNR Am J Neuroradiol       Date:  2014-06-19       Impact factor: 3.825

9.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

Review 10.  Targeting iron metabolism in drug discovery and delivery.

Authors:  Bart J Crielaard; Twan Lammers; Stefano Rivella
Journal:  Nat Rev Drug Discov       Date:  2017-02-03       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.